TableĀ 3

Effect sizes in meta-analysis of studies on GAD in BD

knPrevalence95% CIQp ValueI2 (%)95%CI
Point studiesFE model1229759.6%8.5% to 10.7%
RE model12297511.5%6.6% to 17.4%182.1<0.00194.0%91.2% to 95.9%
RE model without outliers11246712.9%8.2% to 18.6%84.1<0.00188.1%80.7% to 92.7%
RE in subgroup analysis 111278511.6%6.2% to 18.3%183.4<0.00194.5%92.0% to 96.3%
RE in subgroup analysis 212221211.1%6.2% to 17.1%170.1<0.00193.5%90.5% to 95.6%
Subgroup analysis 1: without Simon et al12 and Taman and Ozpoyraz40
Subgroup analysis 2: with BD-I subsample in Simon et al12 and without BD-II subsample in Simon et al,12 BD-II subsample in Chang et al (2012) and Otto et al (2006)
Lifetime studiesFE model18491915.8%14.8% to 16.9%
RE model18491915.1%9.7% to 21.5%318.3<0.00194.7%92.8% to 96.0%
RE in subgroup analysis 18341120.1%12.7% to 28.7%48.8<0.00185.7%73.7% to 92.2%
RE in subgroup analysis 213161612.5%6.4% to 20.1%122.3<0.00190.2%85.1% to 93.6%
RE in subgroup analysis 311160311.2%5.0% to 19.4%110.8<0.00191.0%85.9% to 94.2%
k=number of included studies
n=number of patients in the included studies
Subgroup analysis 1: with BD-I samples only
Subgroup analysis 2: with BD-II and mixed samples
Subgroup analysis 3: with mixed samples only
  • BD, bipolar disorder; FE, fixed-effects model; GAD, generalised anxiety disorders;

  • RE, random-effects model with Bayesian estimator.